Science

Yan Leyfman

Aug 3, 2025, 15:13

Yan Leyfman: New Insights Into Real-World Practices In TE-NDMM

Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Hossam M. Ali et al. published in Clinical Lymphoma, Myeloma and Leukemia:

“New insights into real-world practices in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM):

A national survey of hematologists, oncologists, and plasma cell disorder specialists (May–July 2024) revealed key trends:

Induction:

The quadruplet regimen Dara-VRd (daratumumab, bortezomib, lenalidomide, dexamethasone) was the most widely used across risk groups—78% in high-risk, 63% in standard-risk, and 73% in FISH-unknown cases. Clinicians favored weekly subcutaneous bortezomib, lower-dose dexamethasone, and 25 mg lenalidomide on a 21/28-day cycle.

Maintenance:

Lenalidomide monotherapy was the most common post-transplant approach, though significant variation remains.

MRD Assessment:

Minimal residual disease testing was underutilized, despite growing evidence of its prognostic value.

Practice Variability:

Regimen choice was influenced by provider specialty (with plasma cell experts more likely to use quadruplets), institutional affiliation, and years of experience.

Takeaway:

While antibody-based four-drug induction has become standard in TE-NDMM, the survey underscores continued heterogeneity in post-transplant strategies and a need for greater standardization, especially around MRD monitoring.”

Title: Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey

Authors: Hossam M. Ali, Zainab Yusufali Motiwala, Yara Shatnawi, Jack Khouri, Faiz Anwer, Hussein Awada, Anam Ashfaque, Danai Dima, Louis S Williams, Nausheen Ahmed, Al-Ola Abdallah, Leyla O Shune, Sandra Mazzoni, Muhammad Anns Asif, Maheen Ahmad, Tara Roy, Joslyn Rudoni, Mikhaila Rice, Jonathan Kissam, Diana Basali, Shahzad Raza

You can read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.

Yan Leyfman TE-NDMM research article

More posts featuring Yan Leyfman on OncoDaily.

Al-Ola Abdallah Anam Ashfaque Bortezomib cancer Clinical Lymphoma Danai Dima Dara-VRd Daratumumab dexamethasone Diana Basali Faiz Anwer Hossam M. Ali Hussein Awada Jack Khouri Jonathan Kissam Joslyn Rudoni Lenalidomide Leyla O Shune Louis S Williams Maheen Ahmad Mikhaila Rice MRD MRD monitoring Muhammad Anns Asif multiple myeloma Myeloma and Leukemia Nausheen Ahmed OncoDaily Oncology Sandra Mazzoni Shahzad Raza Tara Roy TE-NDMM transplant-eligible newly diagnosed multiple myeloma Yan Leyfman Yara Shatnawi Zainab Yusufali Motiwala

Hagop Kantarjian: Advances and Revolution in Adult ALL Therapy Over the Last Decade

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Top 10 Immunotherapy Fellowships and Grants to Watch in 2025

July Is Sarcoma Awareness Month: What You Need to Know

Pat Soon-Shiong: SARS-CoV-2 Infection Can Awaken Sleeping Cancer Cells